Hikma Pharmaceuticals Plc Hikma resumes launch of generic Advair Diskus(R) (0951W)

TIDMHIK

RNS Number : 0951W

Hikma Pharmaceuticals Plc

21 April 2021

London, 20 April 2021 - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, annou nces that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus(R)1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.

Hikma will immediately resume launch activities of its generic product for Advair Diskus(R) (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

Siggi Olafsson, Chief Executive Officer of Hikma, said: "We appreciate the FDA's timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus(R) . We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US."

(1) Advair(R) and Advair Diskus(R) are registered trademarks of GSK group of companies.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

 
Susan Ringdal                                [phone]/ +44 7776 
 EVP, Strategic Planning and Global Affairs   477050 
                                              [e-mail] 
Steve Weiss                                  [phone]/ +1 732 788 
 David Belian                                 8279 
 US Communications and Public Affairs         [phone]/[phone] 
                                              [e-mail] 
 

Teneo (Press):

Charles Armitstead / Claire Scicluna [phone]/ [phone]

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBCGDSIXDDGBG

(END) Dow Jones Newswires

April 21, 2021 02:00 ET (06:00 GMT)